Check out your Company Bowl for anonymous work chats.
Novocol Pharma Receives Contribution from the Government of Canada Novocol Pharmaceutical, a long-established sterile injectable fill-finish organization that provides clinical and commercial-scale manufacturing services for global customers, announced today that it will receive a contribution of up to $32.7 million from the Government of Canada to strengthen domestic biomanufacturing capacity. The contribution is made through the Strategic Innovation Fund (SIF) and will support a project to expand Novocol’s GMP facilities in Cambridge, Ontario, with the fill-finish capacity to enhance Canada’s responsiveness to future pandemics.
